Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
PARMA, Italy--(BUSINESS WIRE)--Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, today announced the recipients of its "Find For Rare" research grant program. The independently assessed, expert-led research grant initiative aims to improve patient care and management by recognising innovative research in three lysosomal diseases: Fabry disease, alpha-mannosidosis, and cystinosis.
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
Share
The selected projects demonstrated significant potential to address unmet needs within these rare communities. The recipients include:
Fabry disease: Mitra Tavakoli, University of Exeter, Exeter, UK, for her project "FAB-PAIN: Precise phenotyping of neuropathy using a range of novel biomarkers in Fabry Disease'
Project overview: This project aims to explore a range of novel biomarkers to better understand the pain pathways and its pathophysiology in Fabry disease. The findings may lead to the development of a range of new neuropathic biomarkers, advancing the understanding of disease mechanisms and facilitating the creation of diagnostic tools and therapeutic interventions.
Alpha-mannosidosis: Margarita Dinamarca, University of Basel, Basel, Switzerland, for her project "Investigating brain endothelial dysfunction in alpha-mannosidosis"
Project Overview: This research is significant for its dual contributions: unraveling the mechanisms by which alpha-mannosidosis disrupts endothelial cell function and pioneering a targeted therapeutic strategy using nanocarriers
Cystinosis: Francesco Bellomo, Ospedale Pediatrico Bambino Gesù – IRCCS, Rome, Italy, for his project "Study of molecular mechanisms underlying the effects of ketogenic diet in cystinosis"
Project Overview: This research project investigates the potential of a ketogenic diet to treat nephropathic cystinosis, a rare genetic disorder leading to kidney disease. By studying the diet's effects in murine models, significant reductions in symptoms such as Fanconi syndrome, inflammation, and fibrosis were observed. The project aims to develop an in vitro system to further explore the molecular mechanisms behind these benefits, potentially enabling the discovery of new therapeutic options.
Applications opened for submission on August 08, 2024, and a total of 82 applications from 23 countries were received. All submitted applications were evaluated by a steering committee of 10 independent leading experts in the field of Lysosomal Diseases, who received an honorarium for participating and reviewing the research projects. Details regarding the application criteria can be located here.
"Fabry disease, alpha-mannosidosis, and cystinosis are rare and ultra-rare lysosomal diseases causing severe, progressive, lifelong challenges, often complicated by diagnostic delays due to their complex and gradual progression," said Enrico Piccinini, Senior Vice President, EU and International, Rare Diseases at Chiesi Group. "Further research is vital for better diagnostics, new management options, and improved patient outcomes. The selection of these three projects through 'Find For Rare' highlights our deep commitment to advancing Lysosomal Diseases care by fostering crucial innovation to meet the evolving needs of patients and their families."
Chiesi hosted a ceremony on June 18, 2025, at Chiesi's headquarters in Parma, Italy, to formally recognise the grant recipients and their innovative research.
'The quality and scientific rigor of the proposals submitted to Find For Rare this year were impressive. Each selected project stood out for its potential to address real, day-to-day challenges faced by patients and caregivers affected by lysosomal diseases,' said Prof. Christina Lampe, Chair of the Find For Rare Steering Committee. 'By supporting research that is both innovative and patient-focused, this program helps accelerate the translation of science into meaningful impact for rare disease communities.'
About Find For Rare
The Find For Rare Research Grant Initiative has been designed to support original research projects that advance knowledge in the fields of Fabry disease, alpha-mannosidosis, and cystinosis. The categories of research eligible for funding are projects aimed at improving understanding of the factors affecting diseases, from pathogenesis to progression, and studies of patient tailored clinical management.
Research grants were provided to organisations operating in the health or scientific research sector. Proposals were welcome from all global regions other than the Americas, with application documents required to be in English.
About Lysosomal Diseases
Lysosomal Diseases are inborn errors of metabolism that are characterised by an abnormal build-up of substances in the body's cells as a result of enzyme deficiencies. 1 The build-up of these substances can affect different parts of the body, including the skeleton, central nervous system (brain), lungs, heart, and eyes. Whilst there has been progress in clinical knowledge, more research in Lysosomal Diseases can be beneficial. 1
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.
By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.
UK-CHI-2500657 June 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
IonQ and Kipu Quantum Break New Performance Records For Protein Folding And Optimization Problems
KARLSRUHE, Germany & COLLEGE PARK, Md.--(BUSINESS WIRE)--Jun 19, 2025-- Kipu Quantum, a leader in application and hardware-specific quantum computing solutions, and IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, proudly announced a record achievement: the successful solution of the most complex known protein folding problem ever executed on a quantum computer. This press release features multimedia. View the full release here: IonQ and Kipu Quantum announce the successful solution of the most complex known protein folding problem ever executed on a quantum computer This joint effort is the largest known quantum computation of its kind to-date, and demonstrates the synergy between Kipu's innovative algorithmic framework and IonQ's state-of-the-art hardware. In their latest study, the teams solved: All instances were executed on IonQ's Forte generation systems using Kipu Quantum's flagship BF-DCQO (Bias-Field Digitized Counterdiabatic Quantum Optimization) algorithm. The results advance the frontier of near-term quantum computing and have the potential to make a large impact on biology and drug development. BF-DCQO provides a non-variational, iterative method that is both accurate and resource-efficient. This algorithm can achieve better solutions with fewer quantum operations in each subsequent iteration. This is especially critical for protein folding, where several long-range interactions are present, making the all-to-all connectivity of IonQ's trapped ion systems an important asset. 'Connectivity between qubits in quantum computing impacts efficiency and accuracy. Having all-to-all connectivity means faster time to solution, with higher quality results, and is a unique characteristic of trapped-ion systems. Combining that with Kipu's unique quantum algorithms results in unparalleled performance with minimal resources, a sine qua non path to quantum advantage with IonQ's next-generation system,' said Prof. Enrique Solano, Co-CEO and Co-Founder of Kipu Quantum. 'This collaboration is not only breaking performance records, but is also positioning us to actively pursue quantum advantage using trapped-ion technologies with IonQ for a wide class of industry use cases.' 'Our collaboration with Kipu Quantum has delivered breakthroughs in both speed and quality that sets a new standard for what's possible in quantum computing today,' said Ariel Braunstein, SVP of Product at IonQ. 'This collaboration demonstrates the value of every part of IonQ's quantum computing stack – from the quality of our qubits and how they are connected, to our compiler and operating system to how error mitigation techniques are applied. Kipu's capabilities complement IonQ's cutting-edge systems perfectly and this collaboration is only the first step in our mutual pursuit of near-term commercial value for customers across multiple industries.' IonQ and Kipu Quantum will extend their collaboration with early access to IonQ's upcoming 64-qubit and 256-qubit chips, unlocking the potential to address even larger, industrially relevant challenges. Both companies are exploring additional use cases capable of delivering quantum-advantage in the near term across drug discovery, logistics, and material design. Read the full study here: About Kipu Quantum Kipu Quantum is a world-class German company dedicated to advancing application- and hardware-specific quantum computing solutions across diverse industries. Since its founding in 2021, Kipu Quantum has consistently delivered groundbreaking innovations, achieving runtime quantum advantage and pioneering first quantum products. These advancements underscore the company's commitment to addressing industry-relevant challenges through innovative algorithmic technology. The company offers its solutions as quantum software on its PLANQK platform, which enables frictionless access for more than 220 organizations to integrate quantum solutions into their existing processes. Kipu Quantum is also the pioneer in the core merging of artificial intelligence with quantum computing. Kipu Quantum designs and builds smart agents along quantum workflows involving hardware and software, giving rise to the novel field called Agentic Quantum Computing. Learn more at About IonQ IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems and represent the forefront of the company's technological roadmap as it advances toward its goal of building quantum computers with 2 million physical qubits by 2030. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'accessible,' 'advance,' 'advances,' 'aimed,' 'available,' 'can,' critical,' 'cutting-edge,' 'delivering,' 'forefront,' 'goal,' 'growth,' 'impactful,' 'latest,' 'leading,' 'near term,' 'potential,' 'solving,' 'upcoming,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, accuracy, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; IonQ's ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors; IonQ's ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ's ability to effectively enter new markets; IonQ's ability to deliver services and products within currently anticipated timelines; and IonQ's customers deciding or declining to extend contracts into new phases. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. View source version on CONTACT: Kipu Quantum Contact: Joanna Folberth [email protected] Media Contact: Jane Mazur [email protected] Investor Contact: [email protected] KEYWORD: GERMANY EUROPE UNITED STATES NORTH AMERICA DISTRICT OF COLUMBIA MARYLAND INDUSTRY KEYWORD: HARDWARE SEMICONDUCTOR DATA MANAGEMENT TECHNOLOGY APPS/APPLICATIONS GENERAL HEALTH ARTIFICIAL INTELLIGENCE OTHER TECHNOLOGY SCIENCE SOFTWARE NETWORKS OTHER SCIENCE INTERNET HEALTH RESEARCH SOURCE: IonQ Copyright Business Wire 2025. PUB: 06/19/2025 07:05 AM/DISC: 06/19/2025 07:03 AM
Business Wire
an hour ago
- Business Wire
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia ( has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region. In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM). Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities. 'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.' The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system. 'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.' As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day. The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function. ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes. For more information about ZAP Surgical and the ZAP-X system, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
Business Wire
an hour ago
- Business Wire
Phase Genomics Launches ProxiMeta™ Starter and Elite Bundles to Expand Access to Genome-Resolved Metagenomics
SEATTLE--(BUSINESS WIRE)-- Phase Genomics, Inc., a leader in genomic technology development, today announced the launch of its new ProxiMeta Starter and Elite Bundles, comprehensive product offerings that make genome- and mobilome-resolved metagenomics more accessible for researchers across microbiome, environmental and public health applications. Built on Phase Genomics' award-winning Hi-C metagenomics platform, the streamlined, full-service solutions accelerate discovery from within complex microbial communities. 'We built the ProxiMeta bundles to meet researchers exactly where they are, whether just getting started or leading large-scale research projects. Research doesn't look the same today as it did even last year. Labs are being asked to do more with fewer resources across the board, and we're here to help,' said Ivan Liachko, PhD, CEO and co-founder of Phase Genomics. 'The ProxiMeta bundles offer a flexible platform that evolves with a researcher's career and their science.' The two new bundles provide a scalable entry point for new users and a hands-off option for labs looking to outsource highly specialized technical workflows. The Starter and Elite bundles for Hi-C metagenomics combine robust sequencing, dynamic bioinformatics and personalized scientific support into ready-to-use formats, without the constraints of 16S-based techniques or culturing. The ProxiMeta Starter Bundle is tailored for early-career researchers new to next-generation metagenomics, offering an affordable on-ramp to advanced microbial insights for up to two samples with guaranteed success on library prep. If the initial library preparation fails, Phase Genomics will re-prep the sample at no additional cost. Starter includes hands-on support from Phase Genomics scientists. Learn more here. The ProxiMeta Elite Bundle offers a turnkey, remote extension of lab operations for experienced investigators with active funding and limited bench time. The bundle includes deep metagenomic shotgun sequencing and Hi-C assembly for up to eight samples, performed entirely in-house at Phase Genomics. Learn more here. ProxiMeta Classic is still available as an à la carte option for researchers who prefer to customize their project scope or perform sequencing and analysis in-house. Classic delivers the same high-resolution capabilities with the flexibility of tailored support when needed. The ProxiMeta platform has been heavily cited in leading peer-reviewed journals for its ability to generate high-quality genomes, resolve microbial population structure and link mobile genetic elements like plasmids and phages to their microbial hosts. The ProxiMeta Starter and Elite Bundles are available beginning today, June 19, 2025. For more information or to request a consultation, stop by booth 1109 at ASM 2025 or visit: Follow Phase Genomics on X and LinkedIn for the latest information. About Phase Genomics Phase Genomics applies proprietary ultra-long-range genome sequencing technology to enable genome assembly, microbiome discovery, as well as analysis of genomic integrity and chromosomal aberrations. In addition to a comprehensive portfolio of laboratory and computational services and products, including reagent kits and genomic services, they also offer an industry-leading genome and metagenome assembly and analysis software. Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company's mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.
